Clinical Trials

25 enrolled

Cholangiocarcinoma

NCT06493240 2025-11-25

NLCCRIT-LARC

GastrointestinalGynecologic

Locally Advanced Rectal Cancer

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Phase 1/2 Completed

22 enrolled

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed

291 enrolled

Stomach Neoplasms

NCT04548440 2025-06-12

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT03903705 2025-04-06

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Phase 1/2 Completed

348 enrolled

Advanced Solid Tumor

NCT03812549 2025-03-04

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT04297280 2025-02-27

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT05010668 2025-02-21

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

28 enrolled

Cholangiocarcinoma

NCT06108596 2025-01-21

PICS

33 enrolled

Rectal Neoplasms

NCT03985046 2024-11-07

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

75 enrolled

Esophageal Squamous Cell Carcinoma

NCT04167657 2024-09-19

STAR

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

84 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT04271813 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Neoplasms

NCT04618367 2024-03-06

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Phase NA Completed

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed

600 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT04590599 2023-12-18

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

205 enrolled

Gynecologic

Advanced Cervical Cancer

NCT03802240 2023-11-27

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

492 enrolled

Non-Squamous Non-Small Cell Lung Cancer

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

21 enrolled

Lung Neoplasms

NCT06015035 2023-08-29

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

17 enrolled

Esophageal Neoplasms

NCT05026593 2023-07-19

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

60 enrolled

SCLC

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

42 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

19 enrolled

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

42 enrolled

Advanced Lung Cancer

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

172 enrolled

Advanced Solid Tumor

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

High-Risk Resectable NSCLC

NCT03745170 2023-03-01

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

650 enrolled

Stomach Neoplasms

NCT03150875 2023-02-28

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

290 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03545971 2023-02-28

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

53 enrolled

Advanced Solid Tumors

NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

357 enrolled 14 charts

Squamous NSCLC

NCT03607539 2023-02-27

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

397 enrolled 15 charts

Lung Neoplasms

NCT04177290 2023-02-27

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05118334 2023-02-23

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT03758001 2023-02-22

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

38 enrolled

Advanced Solid Tumor

NCT03568539 2021-06-01

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

39 enrolled 16 charts

Advanced/Metastatic Solid Malignancies

NCT03116152 2021-02-03

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

190 enrolled 14 charts